Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNausea is the most commonly reported side effect when moving to the 5mg Mounjaro dose, and most people who feel sick on 5mg Mounjaro find it settles within one to two weeks as the body adjusts. It is uncomfortable but rarely a sign that something has gone seriously wrong. Mounjaro is a prescription-only medicine; a prescriber assesses your full picture before and during treatment, and any persistent or severe symptoms are a reason to contact your clinical team.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide slows the rate at which your stomach empties. That action sits at the core of how Mounjaro reduces appetite and supports weight loss, but it also means food and stomach acid linger longer than the gut expects. The 2.5mg starting dose gives your system four weeks to begin adapting. When the dose steps up to 5mg, the effect on gastric emptying intensifies, and the nausea that many people felt only mildly at 2.5mg can return more noticeably.
A question our prescribers hear most weeks is whether feeling sicker at 5mg means the treatment should stop. Usually the answer is no. The NHS explains that gastrointestinal side effects, including nausea, vomiting and diarrhoea, are very common with tirzepatide and tend to be most prominent after starting or after a dose change, which is exactly the position you are in at the 5mg stage. The discomfort is real, but it follows a predictable pattern. Most people report that nausea becomes manageable within two weeks.
Knowing why it is happening can make it easier to sit with. This is biology, not intolerance. The dose is doing what it is designed to do; your stomach is simply catching up. The NHS medicines page for tirzepatide side effects lists these GI symptoms in the very common category and notes they generally improve over time.
For most people, the pattern looks like this: nausea peaks in the first two to four days after the injection, then fades gradually before the next weekly dose is due. By the third or fourth injection at 5mg, many people find the worst has passed. That is not guaranteed (individual responses vary) but it is the most commonly reported experience, and it matches what clinical trial participants reported across the SURMOUNT programme.
A smaller group continue to feel noticeably sick beyond the two-week mark. If that describes you, the right move is to speak with your prescriber before deciding whether to continue at 5mg or revisit the titration pace. Staying at a dose longer than planned, or pausing rather than pushing through, are both legitimate clinical options, but they require an actual clinical decision, not a guess.
Timing your injection can help. Some people find that injecting in the evening means the sharpest nausea hits overnight when they are asleep, rather than during the day. Whether that works for you is something to try and discuss with your clinical team. If you are also concerned about appetite levels at 5mg, those questions belong in the same conversation.
Small, consistent changes make the biggest difference. The NHS recommends eating smaller amounts more frequently rather than three large meals, avoiding foods that are rich, spicy or high in fat, and sitting upright for a while after eating rather than lying down. Cold or room-temperature drinks tend to be better tolerated than hot ones. Plain foods (rice, bread, boiled potatoes) sit more comfortably while the stomach is adjusting.
Hydration matters more than it might seem. Nausea suppresses the urge to drink, and mild dehydration then makes nausea worse. Sipping plain water steadily through the day, rather than drinking large volumes at once, is easier on a settling stomach.
Alcohol and carbonated drinks tend to amplify symptoms and are worth avoiding in the early weeks at 5mg. So is eating quickly. Slower meals, chewed thoroughly, ask less of a stomach that is already working more slowly than usual.
None of these steps remove nausea entirely, but they reliably reduce it. Some people combine them with over-the-counter remedies such as ginger products, discuss suitability with a pharmacist or your prescriber. For context on how cost and clinical oversight factor into your overall treatment plan, the Mounjaro cost overview on this site explains what legitimate private treatment should include. Good aftercare access is part of that, not an add-on.
Most nausea at 5mg is uncomfortable but manageable. Some symptoms are a prompt to act sooner. Contact your prescriber or seek medical help if you experience severe vomiting that prevents you keeping fluids down, signs of dehydration (dizziness, very dark urine, feeling faint), or nausea that does not improve at all across three or more weeks at this dose.
There is a more urgent signal to know: severe, persistent abdominal pain that reaches through to the back, with or without vomiting, can be a sign of acute pancreatitis. The MHRA issued a formal Drug Safety Update in January 2026 highlighting this as a known but infrequent risk with GLP-1 medicines. It is rare, but the pain profile is distinct from ordinary nausea, and it needs urgent medical assessment rather than a wait-and-see approach.
If nausea at 5mg is affecting your daily life, that alone is a good reason to get in touch. Our prescribers review patients throughout treatment, not just at the start. You can also read about how sickness at 5mg is managed across different clinical situations, or explore the broader Mounjaro treatment overview for context on the full dose journey. If you are moving up to 7.5mg and want to understand what feeling sick on 7.5mg looks like and how it compares to your current experience, that page covers the next stage in detail. For anything urgent or if you are unsure, the contact page reaches our clinical team directly. If you would like a prescriber to review your current experience and whether treatment is still right for you, speaking to our prescribers is the right next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.